Published in Mental Health Business Week, January 7th, 2006
For the fiscal year ended September 30, 2005, Avanir's net loss was $30.6 million, or $0.30 per share, compared to a net loss of $28.2 million, or $0.36 per share, for the fiscal year ended September 30, 2004.
Total revenues for fiscal 2005 increased to $16.7 million, compared to $3.6 million in fiscal 2004. The increase in revenues is primarily due to licensed technology and research and development services being provided in fiscal 2005 in connection with two new license agreements with AstraZeneca U.K. Limited and Novartis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week